



**Pfizer Announces an [Independent Medical Education Grant RFP](#)  
Local Level Educational Grants Program to Increase Awareness &  
Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)  
*Competitive Grant Program - internal Pfizer review process***

## **I. Background**

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all **independent medical education grants**, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

## II. Eligibility

<b>Geographic Scope:</b>	United States
<b>Applicant Eligibility Criteria</b>	<ul style="list-style-type: none"> <li>• The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.</li> <li>• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. all institutions must have a relevant role and the requesting organization must have a key role in the project.</li> <li>• For projects offering continuing education credit, the requesting organization must be accredited.</li> </ul>

## III. Requirements

<b>Date RFP Issued</b>	<ul style="list-style-type: none"> <li>• February 8, 2021</li> </ul>
<b>Clinical Area</b>	<ul style="list-style-type: none"> <li>• Transthyretin Cardiomyopathy (ATTR-CM)</li> </ul>
<b>General Area of Interest for this RFP:</b>	<ul style="list-style-type: none"> <li>• Projects that will be considered for Pfizer support will focus on improving the care of patients by:             <ul style="list-style-type: none"> <li>• Educating [HCPs] to increase awareness and enable appropriate patient identification by closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment paradigms.</li> <li>• Addressing barriers to appropriate diagnosis and strategies that reduce burdens for patients and providers along the pathway to appropriate diagnosis</li> <li>• Exploring strategies that empower patients to play an active role in understanding TTR amyloidosis and decision making regarding available diagnostic and treatment options</li> <li>• Increasing awareness of the changing epidemiology of TTR amyloidosis with a focus on the prevalence of hereditary ATTR and wild-type ATTR subtypes as the science continues to evolve</li> <li>• Increasing awareness of at risk and undiagnosed populations with TTR amyloidosis with a focus on improving strategies that facilitate the appropriate diagnosis of patients early in the disease course before overt cardiomyopathy has ensued [e.g. populations with electrical disturbances, valvular disease, orthopedic</li> </ul> </li> </ul>

	<p>manifestations, and cardio-oncology diseases (i.e. Light Chain Amyloidosis)]</p> <ul style="list-style-type: none"> <li>Increasing awareness of bone radiotracer scintigraphy as a non-invasive alternative to invasive endomyocardial biopsy for the appropriate diagnosis of TTR cardiac amyloidosis in select patients</li> <li>Supporting the dissemination of information related to the pharmacologic and non-pharmacologic management of ATTR-CM</li> <li>Addressing geographic and racial healthcare disparities</li> <li>Addressing challenges to appropriate diagnoses and caring for patients during an era of increased telehealth utilization</li> <li>Supporting the development of cardiac amyloid centers that provide leadership, best practices, support and/or training of HCPs within a multidisciplinary team environment in order to improve the quality of care for cardiac amyloidosis patients.</li> </ul> <p><i>It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.</i></p>															
<p><b>Target Audience:</b></p>	<p>General Cardiologists, Heart Failure Nurses, Heart Failure Specialists, Echocardiographers, Nuclear Cardiologists, Primary Care Physicians <b>in the Local Setting</b></p>															
<p><b>Expected Approximate Monetary Range of Grant Applications:</b></p>	<ul style="list-style-type: none"> <li>Individual projects requesting up to <b>\$10,000</b> will be considered for <b>small local/community programs</b>.</li> <li>Individual projects requesting up to <b>\$20,000</b> will be considered for <b>large local/community programs</b>.</li> </ul> <p>This RFP will remain open while funds last. Once the full budget is spent the RFP will be closed and new requests will no longer be accepted.</p>															
<p><b>Key Dates:</b></p>	<ul style="list-style-type: none"> <li>RFP release date: February 8, 2021</li> <li>Applications will be accepted on a rolling basis through October but reviewed based on the timelines below:</li> </ul> <table border="1" data-bbox="553 1444 1463 1858"> <thead> <tr> <th>Application Submitted by</th> <th>Decision Notification Date</th> <th>Program Start Date must be after</th> </tr> </thead> <tbody> <tr> <td>March 30, 2021</td> <td>May 1, 2021</td> <td>June 1, 2021</td> </tr> <tr> <td>May 27, 2021</td> <td>July 2, 2021</td> <td>August 1, 2021</td> </tr> <tr> <td>July 29, 2021</td> <td>September 2, 2021</td> <td>October 1, 2021</td> </tr> <tr> <td>September 30, 2021</td> <td>November 2, 2021</td> <td>December 1, 2021</td> </tr> </tbody> </table>	Application Submitted by	Decision Notification Date	Program Start Date must be after	March 30, 2021	May 1, 2021	June 1, 2021	May 27, 2021	July 2, 2021	August 1, 2021	July 29, 2021	September 2, 2021	October 1, 2021	September 30, 2021	November 2, 2021	December 1, 2021
Application Submitted by	Decision Notification Date	Program Start Date must be after														
March 30, 2021	May 1, 2021	June 1, 2021														
May 27, 2021	July 2, 2021	August 1, 2021														
July 29, 2021	September 2, 2021	October 1, 2021														
September 30, 2021	November 2, 2021	December 1, 2021														

	October 28, 2021	December 2, 2021	January 1, 2022
<p><b>How to Submit:</b></p>	<ul style="list-style-type: none"> <li>• Please go to <a href="http://www.cybergrants.com/pfizer/knowledge">www.cybergrants.com/pfizer/knowledge</a> and sign in. First-time users should click “Create your password”.</li> <li>• In the application:             <ul style="list-style-type: none"> <li>○ For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP)</li> <li>○ For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select Yes</li> <li>○ Select the following Competitive Grant Program Name: 2021 RD L- TTR-CM Local Education U.S.</li> <li>○ Select the following Primary Area of Interest: TTR Amyloidosis</li> </ul> </li> <li>• Requirements for submission: Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.</li> <li>• If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.</li> </ul> <p><b>IMPORTANT:</b> Be advised applications submitted after the due date will not be reviewed by the committee.</p>		
<p><b>Questions:</b></p>	<ul style="list-style-type: none"> <li>• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (<a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a>), with the subject line “2021 RD L- TTR-CM Local Education.”</li> </ul>		
<p><b>Grant Agreements:</b></p>	<ul style="list-style-type: none"> <li>• If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click <a href="#">here</a> to view the core terms of the agreement.</li> <li>• Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.</li> </ul>		
<p><b>Review and Approval Process</b></p>	<ul style="list-style-type: none"> <li>• Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.</li> </ul>		

**Mechanism by which Applicants will be Notified:**

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

## Appendix A

### General RFP Submission Requirements

**Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:**

<b>Goals and Objectives</b>	<ul style="list-style-type: none"> <li>Briefly state the overall goal of the project.</li> <li>List the objectives you plan to meet with your project, in terms of learning and expected outcomes.</li> </ul>
<b>Needs Assessment for the Project</b>	<ul style="list-style-type: none"> <li>Include a description of your organization’s needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.</li> </ul>
<b>Target Audience</b>	<ul style="list-style-type: none"> <li>Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.</li> </ul>
<b>Project Design and Methods</b>	<ul style="list-style-type: none"> <li>Describe the planned project, the educational approach, and the way the planned methods address the established need.</li> </ul>
<b>Innovation</b>	<ul style="list-style-type: none"> <li>Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.</li> </ul>
<b>Evaluation and Outcomes</b>	<ul style="list-style-type: none"> <li>In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.</li> </ul>
<b>Dissemination Plan</b>	<ul style="list-style-type: none"> <li>Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.</li> </ul>

<b>Anticipated Project Timeline</b>	<ul style="list-style-type: none"><li>• Provide an anticipated timeline for your project including project start/end dates.</li></ul>
<b>Additional Information</b>	<ul style="list-style-type: none"><li>• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.</li></ul>
<b>Organization Detail</b>	<ul style="list-style-type: none"><li>• Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.</li></ul>
<b>Budget Narrative</b>	<ul style="list-style-type: none"><li>• Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application</li><li>• While estimating your budget please keep the following items in mind:<ul style="list-style-type: none"><li>○ Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).</li><li>○ Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.</li></ul></li></ul>